Clinical trial NCT03509948: A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
Official title: A Phase 1 Open Label, Randomized, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Smoking Cessation
Lead sponsor: Achieve Life Sciences
Sponsor class: INDUSTRY
First posted: 2018-04-27
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This will be an open-label, randomised, 2-treatment period, single-dose crossover study to determine the comparative bioavailability and renal elimination following single-dose administration of 3.0 mg cytisine in healthy smokers under fed and fasted conditions.


Eligibility criteria: Inclusion Criteria:

To be Confirmed at Screening

1. Subject is current cigarette smoker.
2. Healthy males and females between 18 and 55 years of age.

   1. If a female subject of child bearing potential, a negative pregnancy test at screening and admission and willing to use an effective method of contraception (unless of non-childbearing potential or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
   2. If a female subject of non-child bearing potential, a negative pregnancy test at screening and admission. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor.
   3. If a male subject, willing to use an effective method of contraception (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
3. Subject with a body mass index (BMI) of 23-28 kg/m\^2. BMI = body weight in kg / \[height in m\^2\].
4. Subject with no clinically significant abnormal serum biochemistry or haematology values within 28 days before the first dose of cytisine.
5. Subject with negative urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine (a positive result may be repeated at Investigator's discretion).
6. Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results.
7. Subject with no clinically significant abnormalities in 12-lead ECG determined after minimum of 5 minutes in supine position within 28 days before the first dose of cytisine.
8. Subject with no clinically significant abnormalities in vital signs (systolic blood pressure between 90-140 mmHg, diastolic blood pressure (DBP) between 50 and 90 mmHg, and pulse rate (PR) between 40-100 bpm, measured on the dominant arm after minimum of 5 minutes in supine position) determined within 28 days before first dose of cytisine.
9. Subject must be available to complete the study (including post study follow-up) and comply with study restrictions.
10. Subject must provide written informed consent to participate in the study.

To be Re-Confirmed Prior to Dosing

1. Subject continues to meet all screening inclusion criteria (before the cytisine dose).
2. Subject has a negative urinary drugs of abuse screen (including alcohol).
3. Female subject has a negative urine pregnancy test.

Exclusion Criteria:

To be Confirmed at Screening

1. Known hypersensitivity/allergy reaction to varenicline, other cytisine-derivatives or any of the excipients in the Tabex formulation (cellulose, talc, magnesium).
2. History of severe hypersensitivity reactions to any other drugs.
3. History of any medical condition (e.g. gastrointestinal, renal or hepatic) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion).
4. Female subjects who are breast feeding.
5. Difficulty in donating blood on either arm or known history.
6. History of alcoholism or drug abuse within last 2 years.
7. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days (or 5 half-lives, whichever is longer) prior to the cytisine dose, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
8. Participated in any investigational drug clinical trial within the previous 3 months or a marketed drug trial within the previous 30 days prior to randomization on Day 1 of Period 1.
9. Donation of 450 mL or more blood or had history of significant blood loss due to any reason or had plasmapheresis within 3 months before the cytisine dose.
10. Any inability or difficulty in fasting.
11. Inability to communicate well with Investigators (i.e., language problem, poor mental development or impaired cerebral function).
12. Any other condition that the Principal Investigator considers making the subject unsuitable for this study.

To be Re-Confirmed Prior to Dosing:

1. Development of any exclusion criteria since screening.
2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements since screening, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
3. Participation in a clinical study since the screening visit.
4. Donation of 450 mL or more blood since the screening visit.

Primary outcomes:
measure: Maximum Concentration (Cmax)
timeFrame: Pre-dose (within 60 minutes prior to dosing), up to 48 hours post-dose on Days 1-5
measure: Area Under the Concentration Versus Time Curve (AUC) Extrapolated to Infinity (AUC0-∞)
timeFrame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5
measure: Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h)
timeFrame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5
measure: Percent of Total Cytisine Excreted in Urine Over 48 Hours (Ae0-48h%)
timeFrame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5
Secondary outcomes:
measure: Time to Cmax (Tmax)
timeFrame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5
measure: Terminal Elimination Half-Life (T1/2)
timeFrame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5
measure: AUC From Time of Dosing to Last Measurable Concentration (AUC0-t)
timeFrame: Pre-dose (within 60 minutes prior to dosing) up to 48 hours post dose on Days 1-5
measure: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Withdrawal of Study Drug
timeFrame: Baseline (Day 0) through Day 5 plus 6-8 days
measure: Number of Participants With Clinically Significant Biochemistry, Hematology, Urinalysis, and/or 12-lead Electrocardiogram (ECG) Values
timeFrame: Screening through Day 5
Other outcomes:
Locations:
city: Cardiff
country: United Kingdom
facility: Simbec Research Ltd
Study officials:
affiliation: Simbec Research Ltd (Simbec)
name: Ezanul Abd Wahab, MD
role: PRINCIPAL_INVESTIGATOR
References: